Progressing our unique once daily dual mechanism neurokinin antagonist, NT-814, as a potential breakthrough treatment for multiple symptoms of the menopause. Following a successful Phase 2a proof of concept study, NT-814 completed a Phase 2b study, SWITCH-1, with data reported in January 2020. The study demonstrated NT-814’s potential to rapidly and profoundly reduce key symptoms of the menopause. SWITCH-1 found that NT-814 significantly reduced the frequency of hot flashes, which was associated with improvements in quality of life, mood and sleep.
